Early-Onset Hydroxychloroquine Retinopathy and a Possible Relationship to Blood Levels: Comment on the Article by Petri et al

Naoto Yokogawa; Akiko Ohno-Tanaka; Masayuki Hashiguchi; Mikiko Shimizu; Hiroko Ozawa; Shinji Ueno; Kei Shinoda; David J. Browning

doi:10.1002/art.41497

Early-Onset Hydroxychloroquine Retinopathy and a Possible Relationship to Blood Levels: Comment on the Article by Petri et al

Naoto Yokogawa, Akiko Ohno-Tanaka, Masayuki Hashiguchi, Mikiko Shimizu, Hiroko Ozawa, Shinji Ueno, Kei Shinoda, David J. Browning

School of Pharmacy

Research output: Contribution to journal › Letter › peer-review

4 Citations (Scopus)

Original language	English
Pages (from-to)	358-359
Number of pages	2
Journal	Arthritis and Rheumatology
Volume	73
Issue number	2
DOIs	https://doi.org/10.1002/art.41497
Publication status	Published - 2021 Feb

ASJC Scopus subject areas

Immunology and Allergy
Rheumatology
Immunology

Access to Document

10.1002/art.41497

Cite this

@article{53ef43720da4442c8abc2a5bf74ead39,

title = "Early-Onset Hydroxychloroquine Retinopathy and a Possible Relationship to Blood Levels: Comment on the Article by Petri et al",

author = "Naoto Yokogawa and Akiko Ohno-Tanaka and Masayuki Hashiguchi and Mikiko Shimizu and Hiroko Ozawa and Shinji Ueno and Kei Shinoda and Browning, {David J.}",

note = "Funding Information: . Dr. Yokogawa{\textquoteright}s work was supported by a Tokyo Metropolitan Government research grant. Dr. Browning{\textquoteright}s work was supported by the Diabetic Retinopathy Clinical Research Network. Dr. Ueno has received consulting fees and speaking fees from Sanofi (less than $10,000). Dr. Shinoda has received consulting fees and speaking fees from Sanofi (less than $10,000). Dr. Browning owns stock or stock options in Zeiss Meditec. No other disclosures relevant to this letter were reported",

year = "2021",

month = feb,

doi = "10.1002/art.41497",

language = "English",

volume = "73",

pages = "358--359",

journal = "Arthritis and Rheumatology",

issn = "2326-5191",

publisher = "John Wiley and Sons Ltd",

number = "2",

}

TY - JOUR

T1 - Early-Onset Hydroxychloroquine Retinopathy and a Possible Relationship to Blood Levels

T2 - Comment on the Article by Petri et al

AU - Yokogawa, Naoto

AU - Ohno-Tanaka, Akiko

AU - Hashiguchi, Masayuki

AU - Shimizu, Mikiko

AU - Ozawa, Hiroko

AU - Ueno, Shinji

AU - Shinoda, Kei

AU - Browning, David J.

N1 - Funding Information: . Dr. Yokogawa’s work was supported by a Tokyo Metropolitan Government research grant. Dr. Browning’s work was supported by the Diabetic Retinopathy Clinical Research Network. Dr. Ueno has received consulting fees and speaking fees from Sanofi (less than $10,000). Dr. Shinoda has received consulting fees and speaking fees from Sanofi (less than $10,000). Dr. Browning owns stock or stock options in Zeiss Meditec. No other disclosures relevant to this letter were reported

PY - 2021/2

Y1 - 2021/2

UR - http://www.scopus.com/inward/record.url?scp=85097247466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85097247466&partnerID=8YFLogxK

U2 - 10.1002/art.41497

DO - 10.1002/art.41497

M3 - Letter

C2 - 32856370

AN - SCOPUS:85097247466

SN - 2326-5191

VL - 73

SP - 358

EP - 359

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

IS - 2

ER -

Early-Onset Hydroxychloroquine Retinopathy and a Possible Relationship to Blood Levels: Comment on the Article by Petri et al

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this